Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
More papers using
Guangzhou, China. In Acta Pharm Sin B, Sep 2015
Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.
Topographic association of gastric epithelial expression of Ki-67, Bax, and Bcl-2 with antralization in the gastric incisura, body, and fundus
In Gastroenterology Research and Practice, 2001
... calculation, four slides carrying two-sections each were immunohistochemically examined for the p53, Ki-67, Bax, and Bcl-2 expression (Biogenex Laboratories, Inc., San Ramon, ... Cdk5 phosphorylates p53 and regulates its activity.
In PLoS ONE, 2001
... to β-actin, Tau, β tubulin III, RARα, RARβ, p-ERK p-JNK, p-p38, p21, caspase 3, Bax, Bcl-2 and HRP-labeled secondary anti-goat, anti-mouse, and anti-rabbit antibodies were all purchased from Santa Cruz Biotechnology (Santa Cruz, USA) ... Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma
In Cell Death & Disease, 1994
... (1:200, sc-28226, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Bcl-xL (1:500, 610209, BD Transduction Laboratories), anti-Bcl-2 (1:200, sc-492, Santa Cruz Biotechnology), anti-p-eIF2 ... cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2
In Evidence-based Complementary and Alternative Medicine : eCAM, 1990
... Anti-Cdc25c (Cell Signaling Technology Inc., Danvers, MA), anticyclin B1 (Cell Signaling Technology Inc., Danvers, MA), anti-Bcl2 (Cell Signaling Technology Inc., Danvers, MA), ...